(R)-1-(3-chlorophenyl)-3-methylpiperazine | 161800-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-1-(3-chlorophenyl)-3-methylpiperazine
• 英文别名: (3R)-1-(3-chlorophenyl)-3-methylpiperazine；Piperazine, 1-(3-chlorophenyl)-3-methyl-, (3R)-
• CAS: 161800-20-0
• 化学式: C₁₁H₁₅ClN₂
• 分子量: 210.706
• InChiKey: GRBUTWWFTFQSMF-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-1-(3-chlorophenyl)-3-methylpiperazine 在 sodium hydroxide 作用下， 以 丙酮 、 xylene 为溶剂， 反应 20.0h， 生成 2-{3-[(R)-4-(3-Chloro-phenyl)-2-methyl-piperazin-1-yl]-propyl}-2H-[1,2,4]triazolo[4,3-a]pyridin-3-one
  参考文献：
  名称：

  Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5HT_2A and α₁ Receptor Binding Affinity

  摘要：

  A series of triazolopyridine derivatives (compounds 2a-I) were synthesized in order to-explore the effect of modifications of the alkylpiperazine moiety of trazodone (fragment A) on binding affinity for 5HT(2A) and alpha(1) receptors. All of the synthesized compounds show a decrease of affinity for both 5HT(2A) and alpha(1) receptors, as compared to trazodone, with the exception of compounds 2b,c which bear a methyl group in an alpha position to the aliphatic nitrogen atom N-1. These compounds showed a decrease of affinity only for the alpha(1) receptor. The stereochemical influence of the piperazine moiety of compound 2c was also evaluated. Enantiomer (S)-2c showed the most significant differences between 5HT(2A) and alpha(1) receptor affinity (IC50 values) and among the corresponding functional properties (pA(2) values). Since (S)-2c cannot generate the metabolite 4-(3-chlorophenyl)piperazine this product was selected for further pharmacological studies.

  DOI：

  10.1021/jm970700n
• 作为产物：
  描述：

  N-(3-chlorophenyl)-1,2-ethanediamine 在 盐酸 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 14.5h， 生成 (R)-1-(3-chlorophenyl)-3-methylpiperazine
  参考文献：
  名称：

  Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5HT_2A and α₁ Receptor Binding Affinity

  摘要：

  A series of triazolopyridine derivatives (compounds 2a-I) were synthesized in order to-explore the effect of modifications of the alkylpiperazine moiety of trazodone (fragment A) on binding affinity for 5HT(2A) and alpha(1) receptors. All of the synthesized compounds show a decrease of affinity for both 5HT(2A) and alpha(1) receptors, as compared to trazodone, with the exception of compounds 2b,c which bear a methyl group in an alpha position to the aliphatic nitrogen atom N-1. These compounds showed a decrease of affinity only for the alpha(1) receptor. The stereochemical influence of the piperazine moiety of compound 2c was also evaluated. Enantiomer (S)-2c showed the most significant differences between 5HT(2A) and alpha(1) receptor affinity (IC50 values) and among the corresponding functional properties (pA(2) values). Since (S)-2c cannot generate the metabolite 4-(3-chlorophenyl)piperazine this product was selected for further pharmacological studies.

  DOI：

  10.1021/jm970700n

文献信息

• INHIBITORS OF SPHINGOSINE KINASE
  申请人：Stieber Frank

  公开号：US20120252789A1

  公开（公告）日：2012-10-04

  The present invention relates to compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , M 1 , M 2 , M 3 , M 4 , Y 1 , Y 2 , V, W, n, m and o have the meanings given in Claim 1 , and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、M1、M2、M3、M4、Y1、Y2、V、W、n、m和o具有权利要求1中给出的含义，以及其生理上可接受的盐、衍生物、前药、溶剂合物、互变异构体和立体异构体，包括所有比例的混合物，用于治疗受Sph激酶1抑制影响的疾病。
• [EN] PHARMACOLOGICALLY ACTIVE ENANTIOMERS<br/>[FR] ENANTIOMERES PHARMACOLOGIQUEMENT ACTIFS
  申请人：ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE

  公开号：WO1995001354A1

  公开（公告）日：1995-01-12

  (EN) (S) or (R) enantiomer of a compound of formula (IA), where Alk is an alkyl having from 1 to 3 carbon atoms, and an acid addition salt thereof with a physiologically acceptable acid.(FR) L'invention se rapporte à des énantiomères (S) ou (R) de formule (IA) dans laquelle Alk est un alkyle ayant de 1 à 3 atomes de carbone, ainsi qu'à un sel d'addition d'acide de ces composés, que l'on obtient par l'addition d'un acide acceptable physiologiquement.

  （EN）或（R）对于化学式（IA）的化合物的对映体，其中Alk是具有1至3个碳原子的烷基，以及其与一种生理上可接受的酸形成的酸加成盐。（FR）公式（IA）化合物的（S）或（R）对映体，其中Alk是具有1至3个碳原子的烷基，以及其与一种生理上可接受的酸形成的酸加成盐。
• ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS
  申请人：Lopez-Rodriguez Maria Luz

  公开号：US20090036455A1

  公开（公告）日：2009-02-05

  Novel substituted arylpiperazine derivatives with activity as 5-hydroxytryptamine 1A (5-HT 1A ) receptor subtype ligands, to their stereochemical isomers, methods of their preparation, and to their use and to pharmaceutical compositions containing them for the treatment of Parkinson disease, cerebral damage by thromboembolic ictus, craneoencephalic traumatisms, depression, migraine, pain, psychosis, anxiety disorders, aggressive disorders or urinary tract disorders.

  小说替代了具有5-羟色胺1A（5-HT1A）受体亚型配体活性的芳基哌嗪衍生物，包括它们的立体化异构体、制备方法以及它们在治疗帕金森病、血栓栓塞性卒中引起的脑损伤、颅脑外伤、抑郁症、偏头痛、疼痛、精神病、焦虑症、攻击性障碍或泌尿道障碍的药物组成物中的使用。
• N-Hydroxyamide Derivatives and Use Thereof
  申请人：Swinnen Dominique

  公开号：US20080021028A1

  公开（公告）日：2008-01-24

  The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

  本发明涉及公式（I）的N-羟基酰胺衍生物及其用途，特别用于治疗和/或预防自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、癌症、呼吸系统疾病和纤维化，包括多发性硬化症、关节炎、肺气肿、慢性阻塞性肺疾病、肝脏和肺纤维化。
• N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF
  申请人：Swinnen Dominique

  公开号：US20110263628A1

  公开（公告）日：2011-10-27

  The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

  本发明涉及公式（I）的N-羟基酰胺衍生物及其在特定领域的应用，尤其是用于治疗和/或预防自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、癌症、呼吸系统疾病和纤维化，包括多发性硬化、关节炎、肺气肿、慢性阻塞性肺疾病、肝和肺纤维化。